MARKET WIREReuters • 2h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
Why RGNT Stock surged +10.57% Today — RQD Quant Desk Flash
$1.36 +10.57% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.38
Regentis Biomaterials Ltd. (RGNT) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $9.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on RGNT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is RGNT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Regentis Biomaterials Ltd. (NYSE: RGNT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.36 (+10.57% 1D, market cap $9.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RGNT ranks #527 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does RGNT compare to CLGN and CUPR in the Health Care sector?
▼
Within the Health Care sector (Industrial Specialties), RGNT carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLGN (CollPlant Biotechnologies Ltd) holds a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $14.1M). Among the 5-stock peer group, RGNT leads on earnings multiple (N/A) while RGNT leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for RGNT?
▼
Per RGNT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001912966), Regentis Biomaterials Ltd. generated $0 in revenue, -$13.6M in net income, and -$1.4M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.38 (+1.71%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-6.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RGNT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY RGNT SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (27% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (25% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 38.2 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$1.60-6.9% Next Q
52
Q2 (-2Q)Grade D$1.49-14.1% Next Q
49
Q3 (-1Q)Grade D$1.28+6.3% Next Q
47
CurrentGrade D$1.36-6.5% Hist 90D α
44
Trajectory: C- (52) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a RGNT Turnaround Squeeze
While RGNT currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.78) and Max Pain ($1.43) forces dealer call-delta covering toward $16.28.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $RGNT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RGNT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why RGNT Stock surged +10.57% Today — RQD Quant Desk Flash
Regentis Biomaterials Ltd. (RGNT) surged +10.57% to $1.36, trading at 2% of its 52-week range ($1.23 – $15.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.23 – $15.5) with RSI-14 at 38.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.36 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live RGNT Headlines & Catalysts
MARKET WIREReuters • 3h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 5h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 7h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 7h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 8h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 9h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 10h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RGNT)
- ✓Walkthrough of RGNT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
RGNT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.26%🛡️ HOLDING TREND SUPPORT
2026-10-30O $1.42H $1.42L $1.31C $1.36VOL 24.9K
RES: $2.67SUP: $1.21SMA50: $1.78SMA200: $2.92
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
RGNT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on RGNT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for RGNT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RGNT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RGNT)
Health Care Rank #527 of 1016
⚔️ CLGN vs RGNT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (RGNT vs. CLGN, CUPR, LFWD, HSCS)
Industry: Industrial Specialties (55 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Regentis Biomaterials Ltd. (RGNT) ranks #527 by composite RQD confidence (44/100, grade D) and #899 by equity capitalization ($9.6M). Within this direct 5-issuer industry benchmark cohort, RGNT leads on earnings valuation at N/A trailing P/E, while RGNT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CLGN currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with RGNT at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RGNT
ACTIVE
Regentis Biomaterials Ltd. | D | 44/100 | — | — | -35.0% | +10.57% | $9.6M | Benchmark Subject |
| CLGN CollPlant Biotechnologies Ltd | D | 50/100 | — | 64.8% | -35.0% | +11.39% | $12.7M | /clgn-vs-rgnt → |
| CUPR Cuprina Holdings (Cayman) Limited (Class A) | E | 32/100 | — | -1.3% | -35.0% | -1.07% | $14.1M | /cupr-vs-rgnt → |
| LFWD Lifeward Ltd. | D | 46/100 | — | 96.0% | -35.0% | +2.78% | $16.7M | /lfwd-vs-rgnt → |
| HSCS HeartSciences Inc. | D- | 43/100 | — | 59.1% | -35.0% | +7.12% | $17.5M | /hscs-vs-rgnt → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001912966In its most recent audited fiscal period (FY2025, filed 2025-12-31), Regentis Biomaterials Ltd. (RGNT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$13.6M, operating cash flow of -$1.4M, and free cash flow of -$1.4M (-114.5% YoY). On the balance sheet, RGNT closed FY2025 with $7.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$13.6M | -$1.4M | -$1.4M | $7.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $4.8M | -$641.0K | -$641.0K | $482.0K | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$4.1M | -$1.2M | -$1.2M | — | — |
3. RGNT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs RGNT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Regentis Biomaterials Ltd. (NYSE: RGNT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.36 (+10.57% 1D, market cap $9.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RGNT ranks #527 in composite RQD confidence.
How does RGNT compare to CLGN and CUPR in the Health Care sector?
Within the Health Care sector (Industrial Specialties), RGNT carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLGN (CollPlant Biotechnologies Ltd) holds a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $14.1M). Among the 5-stock peer group, RGNT leads on earnings multiple (N/A) while RGNT leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for RGNT?
Per RGNT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001912966), Regentis Biomaterials Ltd. generated $0 in revenue, -$13.6M in net income, and -$1.4M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is RGNT trading relative to its 50-day, 200-day, and 52-week technical levels?
RGNT last traded at $1.36 (+10.57% on volume of 61,904 shares), positioning the stock -23.60% below its 50-day simple moving average ($1.78) and -53.42% below its 200-day simple moving average ($2.92). Across its 52-week range of $1.23 to $15.50, RGNT sits at the 0.9% percentile with a 14-day RSI of 38.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.19 to $1.53).
RGNT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is RGNT stock moving today?
Why RGNT Stock surged +10.57% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.